Market Signal Briefing

Analyst’s Disclosure:I/we have a beneficial long position in the shares of CRWV, AMZN, GOOG either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

The analysis is provided exclusively for informational purposes and should not be considered professional investment advice. Before investing, please conduct personal in-depth research and utmost due diligence, as there are many risks associated with the trade, including capital loss.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Top US Marijuana Stocks to Watch in December 2025
The U.S. cannabis industry continues evolving in 2025. Investors are watching major multi-state operators closely as legalization debates continue. Many traders remain cautious after repeated sector pullbacks. However, long-term growth expectations still look strong. Because of this, investors are searching for companies with real revenue, strong national footprints, and disciplined expansion plans.

Moreover, analysts expect legalization progress to continue during 2026 and 2027. Federal reform still looks uncertain today. Yet state-level expansion continues. Adult-use markets are growing quickly in several states. Medical programs are expanding across other fields. In addition, many states have legalized recreational use. Consequently, large operators with broad footprints continue benefiting from rising demand.

Going into December, three US-focused marijuana stocks deserve attention. These companies include Trulieve, Curaleaf, and Green Thumb Industries. Each company brings something different to the table. Trulieve’s leadership in Florida remains a major strength. Curaleaf holds one of the largest national footprints and international exposures. Meanwhile, Green Thumb continues generating strong revenue growth with disciplined execution. Therefore, these three stocks may appeal to long-term investors watching the sector closely.

[Read More] Cannabis REITs to Watch This December

Top U.S. Marijuana Stocks to Watch This Week

Trulieve Cannabis Corp. (OTC: TCNNF)
Curaleaf Holdings, Inc. (OTC: CURLF)
Green Thumb Industries Inc. (OTC: GTBIF)

Trulieve Cannabis Corp. (TCNNF)
Trulieve remains one of the most recognized U.S. cannabis companies. The company holds its largest presence in Florida. In fact, Trulieve operates more than 190 dispensaries nationwide, with most located in Florida. The company has gradually expanded into Pennsylvania, Arizona, and several other markets. The brand focuses heavily on medical patients. It offers flower, concentrates, edibles, and vape products. Trulieve has earned a strong reputation for consistent product quality. However, it also continues watching recreational developments in many states.

Furthermore, Trulieve recently opened new stores across the Southeast. The company aims to strengthen its presence in medical markets before recreational transitions eventually take place. Although federal reform remains uncertain, Trulieve’s regional dominance in Florida gives it a competitive advantage as legalization expands. As a result, many investors see Trulieve as an important long-term growth story.

Financially, Trulieve continues showing strong revenue performance compared to many peers. The company has reported steady quarterly revenue during 2025. While growth has slowed compared to earlier years, Trulieve still holds one of the strongest financial positions among major U.S. operators. The company has focused on cost management in recent quarters. Therefore, profit margins have shown improvement compared to previous periods.

Additionally, Trulieve continues working on debt reduction and improving financial flexibility. The company remains cautious about expansion spending during slower industry conditions. Management has emphasized operational efficiency and cash flow improvements. Many analysts believe this disciplined strategy reduces long-term risk. Still, the company remains exposed to shifting regulatory conditions and price pressure. Even so, Trulieve’s market leadership in Florida remains a powerful advantage for long-term investors.

[Read More] Top U.S. Marijuana Penny Stocks to Watch in December 2025

Curaleaf Holdings, Inc. (CURLF)
Curaleaf stands among the largest cannabis operators in the United States. The company maintains a wide national footprint, with more than 140 dispensaries. Curaleaf’s largest presence includes New Jersey, Arizona, and Florida. The company continues building a diversified product portfolio. This includes flower, edibles, topicals, and wellness products. Curaleaf also sells CBD and hemp products through national retail chains.

Unlike many competitors, Curaleaf also operates in international markets. The company maintains operations in Europe and sees long-term potential outside the U.S. While international markets remain early, Curaleaf expects future revenue growth across medical regions overseas. Meanwhile, U.S. expansion remains steady as more states advance adult-use legalization. Consequently, Curaleaf continues positioning itself for long-term industry leadership.

From a financial standpoint, Curaleaf remains one of the top revenue producers in the U.S. cannabis sector. The company continues reporting strong sales during 2025. However, profitability remains a challenge similar to most industry peers. Curaleaf has emphasized expense reductions and improved operational efficiency. Management expects margin improvements over the next several quarters.

Moreover, Curaleaf continues managing debt and strengthening its balance sheet. Investors should watch cash levels closely. The company still spends capital expanding markets and product lines. Even so, revenue scale gives Curaleaf a long-term advantage. Analysts expect continued growth if legalization momentum continues. Although short-term volatility remains high, Curaleaf’s broad geographic footprint supports long-term investor confidence.

[Read More] Canadian Cannabis Market Outlook for December 2025: Key Trends for Investors

Green Thumb Industries Inc. (GTBIF)
Green Thumb Industries operates more than 90 stores across the United States. The company’s largest presence includes Illinois, Florida, and Pennsylvania. Green Thumb focuses heavily on branded consumer products. The portfolio includes well-known brands such as RYTHM and Dogwalkers. The company also develops edible and wellness products. Green Thumb has positioned itself around product innovation and brand building.

Additionally, Green Thumb continues expanding its retail presence across important growth markets. Many of these states show rising adult-use demand. The company’s strategy focuses on both retail and wholesale channels. While competition remains intense, Green Thumb has maintained disciplined expansion. Therefore, analysts often describe Green Thumb as one of the most balanced operators in the sector.

Financially, Green Thumb has delivered impressive revenue growth compared to many rivals. The company continues reporting consistent quarterly revenue increases during 2025. Furthermore, Green Thumb has shown strong gross margins relative to peers. The company’s disciplined approach helps protect profitability during industry volatility.

Green Thumb has also maintained controlled expenses and focused resources on the most profitable markets. As a result, cash flow performance continues improving. Analysts have highlighted Green Thumb’s ability to manage growth responsibly. Although risks remain similar to other operators, Green Thumb maintains one of the strongest financial profiles in the industry. Consequently, the company remains an attractive long-term cannabis investment heading into 2026.

[Read More] 3 Great Marijuana Stocks To Help Build Your Long-term Portfolio

Final Thoughts
These three U.S. cannabis leaders remain important names to watch in December 2025. Each company continues navigating challenging industry conditions. However, strong footprints and disciplined financial strategies support long-term potential. While volatility may persist, long-term growth trends continue favoring large multi-state operators.

MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | [email protected]

RADNOR, Pa., Dec. 07, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against StubHub Holdings, Inc. (“StubHub”) (NYSE: STUB) on behalf of those who purchased or otherwise acquired StubHub common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Offering Documents”) issued in connection with StubHub’s September 2025 initial public offering. The lead plaintiff deadline is January 23, 2026.

CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:
If you suffered StubHub losses, you may CLICK HERE or copy and paste the following link into your browser: https://www.ktmc.com/new-cases/stubhub-holdings-inc?utm_source=Globe&mktm=PR

You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected].

DEFENDANTS’ ALLEGED MISCONDUCT:
The complaint alleges that, in the Offering Documents, Defendants made false and/or misleading statements and/or failed to disclose that: (1) StubHub was experiencing changes in the timing of payments to vendors; (2) those changes had a significant adverse impact on StubHub’s free cash flow, including trailing 12 months free cash flow; (3) as a result, StubHub’s free cash flow reports were materially misleading; and (4) that, as a result of the foregoing, Defendants’ positive statements about the company’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

THE LEAD PLAINTIFF PROCESS:
StubHub investors may, no later than January 23, 2026, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation.  The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff.

Kessler Topaz Meltzer & Check, LLP encourages StubHub investors who have suffered significant losses to contact the firm directly to acquire more information.

CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: https://www.ktmc.com/new-cases/stubhub-holdings-inc?utm_source=Globe&mktm=PR

ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: 
Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit www.ktmc.com.

CONTACT:

Kessler Topaz Meltzer & Check, LLP
Jonathan Naji, Esq.
(484) 270-1453
280 King of Prussia Road
Radnor, PA 19087
[email protected]

May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.

HomeDividends AnalysisDividend Strategy

SummaryMy portfolio goal is sustainable, stress-free income—prioritizing safety over chasing high yields.Even though it might be very tempting, tilting investments towards 10%+ yields is not the smartest thing to do.The historical stock market annual return figure is around 10%, which is very difficult to meet for income investors, who are usually concentrated into fixed income factor (lower return potential).In the article I detail why being aggressive on high income investing is likely to turn out to be value destructive and create an income mirage. Jikaboom/iStock via Getty Images

My ultimate objective is to build up a portfolio that would generate sufficient cash flows for me to be in a position where remaining on a payroll becomes a choice, not a necessity.

So, in essence, the objective is very similar to

Analyst’s Disclosure:I/we have a beneficial long position in the shares of PDO,QQQI either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

HomeETFs and Funds AnalysisClosed End Funds Analysis

SummaryNuveen Dynamic Municipal Opportunities Fund (NDMO) offers diversified municipal bond exposure targeting tax-exempt income and capital appreciation.
NDMO has delivered solid performance, validating its role as a tactical play within the muni sector.
The fund's attractive yield remains heavily reliant on return of capital, warranting careful scrutiny.
Munis have lagged other asset classes YTD, reinforcing the need for tactical allocation in NDMO.
Debbie Ann Powell/iStock via Getty Images

Main Thesis & Background The purpose of this article is to evaluate the Nuveen Dynamic Municipal Opportunities Fund (NDMO) as an investment option. This is a diversified municipal bond fund with a variety

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, but may initiate a beneficial Long position through a purchase of the stock, or the purchase of call options or similar derivatives in NDMO, over the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Quick Insights

Recommended For You

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Exxon Mobil (NYSE: XOM) pays an annual dividend of $3.96 per share, yielding 3.38%. The company has raised its dividend for 43 consecutive years, maintaining that streak through the 2020 oil price collapse. The question is whether this dividend remains sustainable as earnings decline from recent peaks.

Metric
Value

Annual Dividend
$3.96 per share

Dividend Yield
3.38%

Consecutive Years of Increases
43 years

Most Recent Payment
December 10, 2025

Dividend Aristocrat Status
Yes

Payout Ratios Show Comfortable Coverage
XOM’s earnings payout ratio stands at 57.6%, calculated from TTM diluted EPS of $6.88 against the $3.96 annual dividend. This leaves substantial room even if earnings soften further.

The free cash flow picture is tighter but healthy. In 2024, XOM generated $30.7 billion in free cash flow (operating cash flow of $55.0 billion minus capex of $24.3 billion) and paid $16.7 billion in dividends. That produces an FCF payout ratio of 54.4%.

Metric
TTM Value
Assessment

Earnings Payout Ratio
57.6%
Healthy

FCF Payout Ratio
54.4%
Healthy

Operating Cash Flow Coverage
3.3x
Strong

The concern is the trend. Net income fell from $55.7 billion in 2022 to $33.7 billion in 2024. Q3 2025 earnings dropped 12.3% year over year. If this decline continues, payout ratios will rise.

A Fortress Balance Sheet Provides Cushion
XOM’s balance sheet is exceptionally strong. Net debt of $53.3 billion against EBITDA of $61.7 billion produces a net debt-to-EBITDA ratio of 0.86x. Interest coverage stands at 53.7x, meaning debt service barely registers against operating income.

Metric
Value
Assessment

Debt-to-Equity
0.26
Conservative

Net Debt-to-EBITDA
0.86x
Low

Interest Coverage
53.7x
Strong

Cash on Hand
$13.9B
Solid Buffer

This financial strength proved critical in 2020, when XOM posted a $22.4 billion loss but maintained the $14.9 billion dividend by drawing on its balance sheet.

The 2020 Test Revealed Both Commitment and Risk
XOM’s 43-year dividend growth streak survived the 2020 pandemic, but required paying dividends from the balance sheet when free cash flow turned negative. The company paid $14.9 billion in dividends against negative $2.6 billion in FCF that year.

Management has since restored profitability. From 2022 through 2024, XOM generated an average of $40.9 billion in annual free cash flow, well above the current $16.7 billion dividend requirement.

This Dividend Is Safe but Cyclicality Remains
Dividend Safety Rating: Safe

XOM’s dividend is secure based on current payout ratios of approximately 55% on both earnings and free cash flow, combined with a conservative balance sheet. The 43-year growth streak reflects genuine commitment.

XOM works for income if oil prices remain above $70 per barrel and the company maintains capital discipline. Watch closely if crude falls below $60, which could pressure both earnings and cash flow enough to threaten dividend growth, though likely not the dividend itself given the balance sheet strength.

, /PRNewswire/ -- 

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Marex Group plc (NASDAQ: MRX) between May 16, 2024 and August 5, 2025, both dates inclusive (the "Class Period"), of the important December 8, 2025 lead plaintiff deadline.

So what: If you purchased Marex securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Marex class action, go to https://rosenlegal.com/submit-form/?case_id=43100 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 8, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, during the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Marex sold over-the-counter financial instruments to itself; (2) Marex had inconsistencies in its financial statements between its subsidiaries and related parties, including as to intercompany receivables and loans; (3) as a result of the foregoing, Marex's financial statements could not be relied upon; and (4) as a result of the foregoing, defendants' positive statements about Marex's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Marex class action, go to https://rosenlegal.com/submit-form/?case_id=43100 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

The market might not appreciate the long-term potential of this AI leader.

Three years since the launch of ChatGPT, it's safe to say generative artificial intelligence is more than just a passing fad. The innovations of the past few years have the potential to affect a wide range of businesses, and a handful of companies have been at the forefront of the efforts.

Nvidia (NVDA 0.53%) and Palantir Technologies (PLTR +2.19%) are two of the biggest beneficiaries of investor optimism around AI. One makes the essential infrastructure for building better large language models while the other provides the software backbone that enables all sorts of businesses to harness the power of those models.

Both companies have seen their stocks soar over the past three years on the back of strong financial results. More recently, though, they've both seen pullbacks in their stock prices, and investors may be thinking whether now is the opportunity they've been waiting for to invest in the tech giants.

But a pullback in another stock could be even more appealing for long-term investors who expect artificial intelligence to play a pivotal role in the future. Here's why readers should take a closer look at Meta Platforms (META +1.80%) as an incredible opportunity to capitalize on the advances of artificial intelligence.

Image source: Getty Images.

Why the market is giving investors a great deal
Shares of Meta declined sharply after the company reported its third-quarter earnings. The company continues to produce strong operating results, though. Revenue climbed 26% year over year last quarter, and earnings per share (adjusted for a one-time non-cash tax expense) came in well above expectations, growing 20% year over year.

The thing that has investors pulling away from the stock is Meta's plans for AI spending. The company saw a big step-up in spending this year, and that's already reflected in its income statement. The operating margin compressed 3 percentage points last quarter, although it's still a healthy 40%. Management said it's planning to spend even more on AI data centers in 2026.

It's essential to note that data center spending requires a significant up-front investment, but those expenses are recognized over time as the assets depreciate, ultimately affecting the income statement. Meta's management estimates the useful lives of the servers in its data centers to be five-and-a-half years, so it amortizes the expense over that period on its income statement.

As spending continues to increase year after year, operating costs will also continue to rise. And if Meta's estimate of useful lives is too favorable, it could end up taking a big hit on its income statement at some point down the line as it accelerates the depreciation expense.

Another point of concern for investors recently is the use of off-balance-sheet financing using special purposive vehicles. Meta used a joint venture to raise debt to finance its $27 billion data center planned for Louisiana. That debt won't show up on Meta's balance sheet, but it's a notable position for the company and should be factored into its valuation.

Perhaps after Meta spent heavily to build out Reality Labs without much to show for it, investors are wary of the tens of billions that Meta plans to spend on AI every year. But the tech giant is well-positioned to benefit from further advances in generative AI, and it's already showing excellent financial results.

Today's Change

(

1.80

%) $

11.89

Current Price

$

673.42

One of the biggest beneficiaries of generative AI
Meta could ultimately benefit more from more capable generative AI than any company in the world. It could provide a significant boost to its already massive advertising business.

Meta has historically grown its advertising business in cycles. It creates a product, builds engagement, and then turns on the ad faucet. As it ramps up advertising on a certain surface (like Feeds, Stories, or Reels), it usually sees a decline in the average price per ad as supply increases. As marketers learn to optimize new ad formats, they experience improved returns on investment, and the average price per ad increases until the market reaches equilibrium again.

Meta recently started showing ads in Threads and WhatsApp in addition to producing improved engagement on Instagram and Facebook. The result was a 14% increase in ad impressions last quarter. But the average price per ad also increased, up 10% year over year.

Meta's artificial intelligence capabilities are a key reason why. Meta's AI is getting better at targeting advertisements to users. On top of that, it's helping marketers iterate on their ad campaigns to make advertisements more effective and appeal to more users. As a result, users are seeing increasingly relevant ads.

But that's just the tip of the iceberg. Meta is developing an AI agent that can create and manage ad campaigns for a business. That can put small businesses, which make up the majority of Facebook and Instagram advertisers, on a level playing field with big corporations that have dedicated ad teams. As a result, Meta could expand the budgets for many of its advertisers and bring in new marketers to its platform.

Lastly, generative AI could also expand the output of content creators, producing tons of content for Facebook and Instagram. As a result, engagement on the two social media apps could continue climbing as users find a growing catalog of tailor-made content. That should increase ad inventory, providing more space for the influx of advertisers from AI-assisted campaigns to see strong returns on their ad spend.

But getting to that point will cost money. At Meta's scale, licensing another developer's AI models doesn't make sense. It has to build it. That means lots of data centers and high research and development costs.

Why it's a great opportunity right now
After the pullback in share price, Meta stock trades for less than 22 times analysts' expectations for 2026 earnings. That's an incredible price for a stock that's growing its bottom line at a 20% rate, fueled by strong revenue growth. The price is far more attractive than the ultra-expensive Palantir, which trades for well over 200 times earnings. It's also more attractive than Nvidia, which has high growth expectations but faces growing challenges and risks.

While Meta's bottom-line growth might slow temporarily as more AI expenses show up on the income statement, the top line should continue to climb at a steady pace thanks to the improvements it's making in the ad business. As AI spending levels off, it should demonstrate operating leverage once again, with an expanding operating margin, indicating a long runway for earnings growth.

The stock isn't without risks, but at the current price, the downside is a lot smaller than the upside.

December 07, 2025 8:45 AM EST | Source: Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in StubHub to Contact Him Directly to Discuss Their Options

If you purchased or otherwise acquired stock of StubHub pursuant and/or traceable to StubHub's registration statement for the initial public offering held on or about September 17, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against StubHub Holdings, Inc. ("StubHub" or the "Company") (NYSE: STUB) and reminds investors of the January 23, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

The complaint filed in this class action alleges that Registration Statement was materially false and/or misleading and failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the Company was experiencing changes in the timing of payments to vendors; (2) those changes had a significant adverse impact on free cash flow, including trailing 12 months ("TTM") free cash flow; (3) as a result, the Company's free cash flow reports were materially misleading; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

On September 17, 2025, StubHub conducted its IPO, selling approximately 34 million shares of Class A common stock at $23.50 per share.

On November 13, 2025, after the market closed, StubHub issued a press release announcing financial results for the third quarter 2025, which ended September 30, 2025. The press release revealed free cash flow of negative $4.6 million in the quarter, a 143% decrease from the Company's free cash flow in the year ago period, which was positive $10.6 million. The press release further revealed the Company's net cash provided by operating activities was only $3.8 million, a 69.3% decrease from the year ago period, where the Company reported $12.4 million in net cash provided by operating activities.

On the same date, the Company filed its Form 10-Q for the same quarterly period ended September 30, 2025, with the SEC. The quarterly report revealed that this year-over-year decrease "primarily reflects changes in the timing of payments to vendors."

On this news, StubHub's stock price fell $3.95 per share, or 20.9%, to close at $14.87 per share on November 14, 2025, on unusually heavy trading volume.

By the commencement of this action, the Company's stock was trading as low as $10.31 per share, a nearly 56% decline from the $23.50 per share IPO price.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding StubHub's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the StubHub Holdings, Inc. class action, go to www.faruqilaw.com/STUB or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277127

December 07, 2025 8:52 AM EST | Source: Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in DeFi Technologies to Contact Him Directly to Discuss Their Options

If you purchased or acquired securities in DeFi Technologies between May 12, 2025 and November 14, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against DeFi Technologies Inc. ("DeFi Technologies" or the "Company") (NASDAQ: DEFT) and reminds investors of the January 30, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (i) DeFi Technologies was facing delays in executing its DeFi arbitrage strategy, which at all relevant times was a key revenue driver for the Company; (ii) DeFi Technologies had understated the extent of competition it faced from other DAT companies and the extent to which that competition would negatively impact its ability to execute its DeFi arbitrage strategy; (iii) as a result of the foregoing issues, the Company was unlikely to meet its previously issued revenue guidance for the fiscal year 2025; (iv) accordingly, Defendants had downplayed the true scope and severity of the negative impact that the foregoing issues were having on DeFi Technologies' business and financial results; and (v) as a result, Defendants' public statements were materially false and misleading at all relevant times.

On November 6, 2025, DeFi Technologies issued a press release purporting to report an arbitrage trade by DeFi Alpha. The press release disclosed, inter alia, that "[DAT]s have absorbed or delayed a significant share of arbitrage opportunities over the past year."

On this news, DeFi Technologies' stock price fell $0.13 per share, or 7.43%, to close at $1.62 per share on November 6, 2025.

Then, on November 14, 2025, DeFi Technologies issued a press release reporting its financial results for the third quarter of 2025. Among other items, DeFi Technologies reported a revenue decline of nearly 20%, falling well short of market expectations. The Company also significantly lowered its 2025 revenue forecast, from $218.6 million to approximately $116.6 million, and attributed this reduction to "a delay in executing DeFi Alpha arbitrage opportunities previously forecasted due to the proliferation of [DAT] companies and the consolidation in digital asset price movement in the latter half of 2025."

Concurrently, DeFi Technologies announced that Defendant Newton would leave his role as CEO and transition to an advisory position.

Following these disclosures, DeFi Technologies' stock price fell $0.40 per share, or 27.59%, over the following two trading sessions, to close at $1.05 per share on November 17, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding DeFi Technologies's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the DeFi Technologies class action, go to www.faruqilaw.com/DEFT or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277111

, /PRNewswire/ --

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the "Class Period"), of the important December 15, 2025 lead plaintiff deadline.

So what: If you purchased MoonLake common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the MoonLake class action, go to https://rosenlegal.com/submit-form/?case_id=45681 mailto:or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. If you wish to serve as lead plaintiff, you must move the Court no later than December 15, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved, at that time, the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the complaint, throughout the Class Period, defendants made false and/or misleading statements, as well as failed to disclose material facts, regarding the distinction between the Nanobodies and monoclonal antibodies, including that: (1) SLK and BIMZELX share the same molecular targets (the inflammatory cytokines IL-17A and IL-17F); (2) SLK's distinct Nanobody structure would not confer a superior clinical benefit over the traditional monoclonal structure of BIMZELX; (3) SLK's distinct Nanobody structure supposed tissue penetration would not translate to clinical efficacy; and (4) based on the foregoing, defendants lacked a reasonable basis for their positive statements regarding SLK's purported superiority to monoclonal antibodies. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the MoonLake Immunotherapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=45681 or mailto:call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

      Laurence Rosen, Esq.
      Phillip Kim, Esq.
      The Rosen Law Firm, P.A.
      275 Madison Avenue, 40th Floor
      New York, NY 10016
      Tel: (212) 686-1060
      Toll Free: (866) 767-3653
      Fax: (212) 202-3827
      [email protected]
      www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

A beaten-down diagnostics stock is quietly tightening margins and drawing fresh institutional conviction—here’s what that means for long-term investors.

On November 14, New York City-based Newtyn Management disclosed a purchase of 994,332 shares of QuidelOrtho Corporation (QDEL), increasing its stake by approximately $30.4 million.

What HappenedAccording to a filing with the Securities and Exchange Commission dated November 14, Newtyn Management reported buying 994,332 additional shares of QuidelOrtho Corporation (QDEL) during the third quarter. This raised its total position to 2.7 million shares with a reported value of $79.5 million as of September 30.

What Else to KnowThe fund's QDEL stake now represents 9.7% of its $816.9 million in 13F reportable assets.

Top holdings after the filing: 

NASDAQ:INDV: $101.3 million (12.4% of AUM)NASDAQ:QDEL: $79.5 million (9.7% of AUM)NASDAQ:TBPH: $72.3 million (8.8% of AUM)NYSE:AD: $67.5 million (8.3% of AUM)NYSE:CNNE: $62.5 million (7.6% of AUM)As of November 14, QDEL shares were priced at $27.76, down 26% over the past year and well underperforming the S&P 500, which is up 13% in the same period.

Company OverviewMetricValueRevenue (TTM)$2.7 billionNet Income (TTM)($1.2 billion)Price (as of Friday)$27.761-Year Price Change(26%)Company SnapshotQuidelOrtho Corporation develops and manufactures diagnostic testing technologies, including clinical chemistry instruments, immunoassay systems, blood typing and donor screening tools, and point-of-care and molecular diagnostic products.The company generates revenue through direct sales and distribution of diagnostic equipment and consumables to healthcare providers, laboratories, blood banks, and retail channels.It serves hospitals, clinical and reference laboratories, urgent care and retail clinics, blood banks, donor centers, and international markets in North America, EMEA, China, and beyond.QuidelOrtho Corporation is a leading provider of diagnostic testing solutions, operating at scale with a global footprint and a diversified product portfolio. The company leverages expertise in laboratory, transfusion medicine, point-of-care, and molecular diagnostics to address a broad range of healthcare testing needs.

Its strategy centers on innovation in diagnostic technologies and expanding access to rapid and accurate testing for both professional and consumer markets. This diversified approach supports resilience and positions the company as a key player in the global diagnostics industry.

Foolish TakeLong-term investors will likely view Newtyn’s move as a high-conviction bet on a deeply discounted diagnostics play trying to reset its fundamentals after a turbulent few years. QuidelOrtho’s shares have shed nearly 90% of their value since 2020, but the company’s latest quarter showed signs of stabilization in its core business even as headline results were overshadowed by a $701 million goodwill impairment tied to its lower market valuation. Beneath that non-cash charge, non-respiratory revenue grew 5% as reported, lab revenue increased 5%, and adjusted EBITDA margin expanded to 25%, up 180 basis points from last year.

For a value-oriented fund like Newtyn—whose portfolio already skews toward complex special situations—doubling down on QDEL fits a pattern: leaning into distressed but cash-generating companies with pathways to operational improvement. With adjusted EPS of $0.80, rising cost efficiencies, and narrowed full-year guidance, the underlying trajectory may look more durable than the stock chart suggests. Ultimately, it'll be important to watch whether margin gains continue as COVID revenue declines stabilize, and whether the company can maintain growth in labs, immunohematology, and point-of-care as it winds down donor screening.

Glossary13F: A quarterly report filed by institutional investment managers to disclose their equity holdings.
Assets Under Management (AUM): The total market value of investments managed by a fund or firm on behalf of clients.
Stake: The ownership interest or share held in a company by an investor or fund.
Holding: A security or asset owned by an investor or fund.
Filing: An official submission of required documents or reports to a regulatory authority, such as the SEC.
Point-of-Care: Medical testing performed at or near the site of patient care rather than in a centralized laboratory.
Molecular Diagnostics: Techniques that analyze biological markers in the genome and proteome to diagnose and monitor disease.
Consumables: Products that are used up during diagnostic testing, such as reagents or test cartridges.
Transfusion Medicine: The branch of medicine focused on the transfusion of blood and blood components.
EMEA: Geographic region including Europe, the Middle East, and Africa.
13F Reportable Assets: Securities that must be disclosed in a fund's 13F filing with the SEC.
TTM: The 12-month period ending with the most recent quarterly report.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends QuidelOrtho. The Motley Fool has a disclosure policy.

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

HomeETFs and Funds AnalysisETF Analysis

SummaryThe Schwab Fundamental U.S. Small Company ETF offers diversified small-cap exposure with fundamental weighting, contrasting VUG's concentrated large-cap technology focus.VUG's top 10 holdings comprise 60.9% of assets, with 63.3% of the ETF in technology, exposing it to significant sector-specific downside risk.FNDA's valuation appears relatively attractive versus the Russell 2000 and S&P 500, though not cheap in absolute terms; it lags VUG's recent performance.I rate FNDA a hold, favoring SMDV for defensiveness, but recommend reducing VUG and adding FNDA or VBR for diversification.pepifoto/iStock via Getty Images

This piece follows up a similar idea that I shared last month, to sell VTI and buy VBR. Since that article was published, both ETFs are up about the same. The big idea from that article was to

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

HomeStock IdeasLong IdeasBasic Materials

SummaryRio Tinto is regaining internal order. Q3 showed stable operations, clearer execution, and a simplified structure that finally aligns decisions with scale and reduces noise that previously clouded the investment case.The shift to three product groups improves focus, accountability, and long-term efficiency, reinforcing a strategic direction that was missing months ago and giving more coherence to a business often viewed.Strong margins, a 5% dividend yield, and an undemanding 11x P/E show a valuation still anchored in last semester’s weakness, not in the operational discipline and clarity emerging through recent events.Risks remain, mainly iron dependence and project execution, but the combination of better internal alignment, stable production, and a discounted multiple strengthens the risk-reward, supporting my decision to move to buy.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Quick Insights

Recommended For You

R289 continues to be generally well tolerated and at doses of ≥500 mg QD preliminary efficacy was observed in elderly, heavily pre-treated lower-risk MDS patients RBC-TI was achieved by 33% (6/18) of evaluable transfusion dependent patients receiving R289 doses ≥500 mg QD, including 40% (2/5) in the 500 mg BID dose group SOUTH SAN FRANCISCO, Calif. , Dec. 7, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced updated data from its ongoing Phase 1b study evaluating R2891, an oral prodrug of R835, a potent and selective dual inhibitor of interleukin receptor-associated kinases 1 and 4 (IRAK1/4), in patients with relapsed or refractory (R/R) lower-risk myelodysplastic syndrome (MDS).

Anthony Scaramucci joins The Watch List to talk about his new book, 'Solana Rising,' and why the cryptocurrency will be one of the biggest market stories over the next five years. He takes investors through the altcoin space and the opportunities he sees in crypto beyond Bitcoin.

December 07, 2025 8:03 AM EST | Source: Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Blue Owl to Contact Him Directly to Discuss Their Options

If you purchased or acquired securities in Blue Owl between February 6, 2025 and November 16, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Blue Owl Capital Inc. ("Blue Owl" or the "Company") (NYSE: OWL) and reminds investors of the February 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) that Blue Owl was experiencing a meaningful pressure on its asset base from BDC redemptions; (2) that, as a result, the Company was facing undisclosed liquidity issues; (3) that, as a result, the Company would be likely to limit or halt redemptions of certain BDCs; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On November 16, 2025, the Financial Times published an article describing how "Blue Owl has blocked redemptions in one of its earliest private credit funds as it merges with a larger vehicle overseen by the asset manager in a deal that could leave investors with large losses."

According to the report, Blue Owl Capital Corporation II investors are restricted from pulling money from the fund until a recently announced merger with Blue Owl Capital Corporation closes in early 2026.

The article further explains how, once the merger occurs, investors in Blue Owl Capital Corporation II will permanently lose the ability to redeem cash at the fund's Net Asset Value (NAV). Instead, investors will trade their shares in for the publicly traded Blue Owl Capital Corporation shares, which are currently trading approximately 20% under the fund's NAV.

On this news, Blue Owl's stock price fell $0.85, or 5.8%, to close at $13.77 per share on November 17, 2025, thereby injuring investors.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Blue Owl's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Blue Owl Capital class action, go to www.faruqilaw.com/OWL or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277108

December 07, 2025 08:05 ET

 | Source:

Prime Medicine, Inc.

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the publication of Phase 1/2 clinical data with PM359, the Company’s investigational autologous hematopoietic stem cell product for p47phox chronic granulomatous disease (CGD) in the New England Journal of Medicine (NEJM). The data will also be presented in a poster session at the 67th American Society of Hematology (ASH) Annual Meeting, December 6-9, 2025 in Orlando, Florida.

The publication, titled “Prime Editing for p47-phox Chronic Granulomatous Disease,” reports initial data for two patients treated in the Phase 1/2 trial of PM359, which was designed to assess safety, biological activity and preliminary efficacy in adult and pediatric study participants. Both patients experienced rapid neutrophil and platelet engraftment, as well as durable restoration of NADPH oxidase activity and early clinical benefit, without any safety concerns. Together, these results provide the first-in-human demonstration of the safety and efficacy of Prime Editing, and support the potential for PM359 as a precise therapeutic strategy for CGD:

Both patients enrolled in the study had a history of prior CGD-defining complications, including CGD-associated colitis (CAC), and skin and soft tissue infections, and both were maintained on long-term prophylactic therapy.Both patients experienced rapid neutrophil engraftment, achieving 69% and 83% dihydrorhodamine-positive (DHR+) neutrophils by Day 30, respectively, far in excess of the 20% projected minimum threshold for clinical benefit. DHR activity remained stable over time in both patients, suggesting that gene correction occurred in the long-term repopulating hematopoietic stem cells (HSCs) of the bone marrow.Both patients remain free of new CGD-related complications or significant intercurrent illnesses post-infusion; additionally, Patient 1 stopped his mesalamine treatment and has not experienced a flare of CAC, and Patient 2’s levels of fecal calprotectin have decreased substantially, and his chronic CAC symptoms have abated.No clinically significant adverse events attributable to PM359 occurred in either patient, and all observed toxicities were consistent with busulfan-based conditioning. “Publication of these first-in-human data highlights Prime Editing’s promise as a next-generation therapeutic platform, which is capable of delivering meaningful benefits to patients and which can be manufactured and delivered at clinical scale,” said Mohammed Asmal, M.D., Ph.D., Chief Medical Officer of Prime Medicine. “Beyond demonstrating early clinical efficacy, these results offer important insights into Prime Editing’s safety profile and potential advantages over other gene editing technologies. As described in the NEJM publication, we observed high recovery rates of viable corrected cells after a single mobilization cycle, as well as the rapid reconstitution of the hematopoietic system after infusion. Both support our belief that the mechanism of Prime Editing, which does not induce double-strand breaks, may be better tolerated by HSCs and other cell types – and therefore safer for patients – than other approaches.”

About Prime Medicine
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing’s versatile gene editing capabilities could unlock opportunities across thousands of potential indications.

Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: liver, lung, and immunology and oncology. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path, and each expected to provide the foundation for expansion into additional opportunities. Over time, the Company intends to maximize Prime Editing’s broad and versatile therapeutic potential, as well as the modularity of the Prime Editing platform, to rapidly and efficiently expand beyond the diseases in its current pipeline, potentially including additional genetic diseases, immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases, which collectively impact millions of people. For more information, please visit www.primemedicine.com.

© 2025 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements about Prime Medicine’s beliefs and expectations regarding: the significance of data from its Phase 1/2 trial of PM359; the potential for PM359 to be a precise and safe therapeutic strategy for CGD;; the safety and efficacy of Prime Editing, including in comparison to other approaches; the potential of Prime Editing to correct the causative mutations of, and to cure, diseases; its strategic plans for its business, programs, and technology; and the potential of Prime Editing to unlock opportunities across thousands of potential indications.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, risks associated with: uncertainties related to Prime Medicine’s product candidates entering clinical trials; the authorization, initiation, and conduct of preclinical and IND-enabling studies and other development requirements for potential product candidates, including uncertainties related to opening INDs and obtaining regulatory approvals; risks related to the development and optimization of new technologies, the results of preclinical studies, or clinical studies not being predictive of future results in connection with future studies; the scope of protection Prime Medicine is able to establish and maintain for intellectual property rights covering its Prime Editing technology; Prime Medicine’s ability to identify and enter into future license agreements and collaborations; Prime Medicine’s expectations regarding the anticipated timeline of its cash runway and future financial performance; and general economic, industry and market conditions. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in Prime Medicine’s most recent Annual Report on Form 10-K, as well as any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent Prime Medicine’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Prime Medicine explicitly disclaims any obligation to update any forward-looking statements subject to any obligations under applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.

Investor and Media Contacts
Gregory Dearborn
Prime Medicine
857-209-0696
[email protected] 

Hannah Deresiewicz
Precision AQ
212-362-1200
[email protected]

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

Costco Wholesale Corporation (NASDAQ: COST) and Walmart Inc. (NYSE: WMT) both closed out strong quarters recently, revealing two very different strategies for winning in retail. Costco leaned into its membership warehouse model with e-commerce expansion. Walmart went all-in on omnichannel transformation and marketplace growth.

E-Commerce Growth Tells Two Different Stories
Walmart’s digital business exploded 27% in Q3, driven by store-fulfilled delivery, marketplace expansion, and aggressive investments in digital infrastructure. The company spent $18.6 billion on capital expenditures this year, much aimed at logistics and technology supporting same-day delivery and pickup. CFO John David Rainey emphasized “enhancing the digital customer experience” during the earnings call.

Costco’s e-commerce grew 13.6% in Q4, solid but far slower than Walmart’s pace. The company operates 914 warehouses globally and continues prioritizing the in-store bulk buying experience that defines its model. E-commerce supports the core business rather than transforming it. Comparable sales rose across all regions.

Walmart’s international segment jumped 10.8% to $33.5 billion in net sales, while Sam’s Club added $23.6 billion with 3.1% growth. The breadth of Walmart’s portfolio gives it more levers to pull when one segment softens.

Membership Model vs. Omnichannel Flexibility
Costco’s strategy revolves around membership fees and bulk purchasing. The model creates predictable revenue and keeps customers locked into the ecosystem. Net income grew 10.9% to $2.61 billion, and profit margin held at 2.94%. Operating margin of 3.88% reflects the thin-margin, high-volume approach that has worked for decades.

Walmart’s net income surged 33.0% to $6.09 billion, though operating income stayed flat due to share-based compensation charges related to PhonePe. The company raised full-year guidance to adjusted EPS of $2.58 to $2.63. Gross margin grew slower than revenue, indicating pricing pressure, but scale and diversification provide cushion.

Metric
Costco
Walmart

E-Commerce Growth
13.6%
27%

Net Income Growth
10.9%
33.0%

Operating Margin
3.88%
3.73%

P/E Ratio
49.02
40.39

Walmart’s marketplace and digital infrastructure give it flexibility Costco doesn’t have. Costco’s warehouse model limits how fast it can scale and where it can compete. But that constraint also creates discipline.

What I’m Watching Into 2026
I will be watching whether Walmart can sustain 27% e-commerce growth without crushing margins further. The capital spending is massive, and the payoff needs to show up in profitability soon. Costco’s challenge: can it accelerate digital growth without diluting the membership value proposition?

Walmart’s international strength and Sam’s Club stability give it more ways to win if U.S. retail softens. Costco’s global footprint is solid but less diversified. Both companies face input cost volatility and consumer spending uncertainty heading into 2026.

Why I Lean Toward Walmart for Growth Investors
If you want a turnaround story with momentum, Walmart looks more compelling right now. The 33% net income growth and 27% e-commerce surge show the digital transformation is working. The stock trades at 40x earnings compared to Costco’s 49x, offering better value for the growth rate.

Costco fits defensive investors better. As one Reddit user put it: “For me, my best investment was probably Costco. I bought in March during that random dip and just held. Boring but solid.” That sums up the appeal. Steady, predictable, reliable.

Walmart may appeal more to investors focused on omnichannel retail growth and digital transformation. Costco may fit better for those prioritizing stability and the proven membership model during economic volatility.

It would currently cost investors starting from scratch over $11,000.

One of the better parts of investing in stocks is the passive income you can receive from owning dividend stocks or exchange-traded funds (ETFs). It's a way of receiving value from your stocks without relying solely on stock price appreciation, though both are appreciated.

A popular go-to dividend ETF is the SPDR Portfolio S&P 500 High Dividend ETF (SPYD 0.16%), which has a trailing yield of 4.46% at the time of this writing. At that yield, you'd need to own about 256 shares of SPYD to receive $500 in annual dividend income. At its current price of $43.86 per share, that would cost you around $11,210.

Image source: Getty Images.

SPYD's 4.46% dividend yield is among the higher yields you'll find in a broad dividend ETF, but it makes sense given that the ETF tracks the top 80 high-dividend-yielding companies in the S&P 500 (an index of the 500 largest American companies).

Today's Change

(

-0.16

%) $

-0.07

Current Price

$

43.40

By investing in a high-yielding dividend ETF like SPYD, you get a payout that's close to four times higher than the S&P 500 average, exposure to 78 companies spanning all 11 major U.S. sectors, and a cheap ETF whose expense ratio is only 0.07%. The latter works out to paying only $0.70 per $1,000 invested in SPYD, which is easily made up by the dividends you receive.

Stefon Walters has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

December 07, 2025 8:10 AM EST | Source: Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Baxter To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Baxter between February 23, 2022 and Ocober 29, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Baxter International Inc. ("Baxter" or the "Company") (NYSE: BAX) and reminds investors of the December 15, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (a) the Novum LVP suffered systemic defects that caused widespread malfunctions, including underinfusion, overinfusion, and complete non-delivery of fluids, which exposed patients to risks of serious injury or death; (b) Baxter was notified of multiple device malfunctions, injuries, and deaths from these defects; (c) Baxter's attempts to address these defects through customer alerts were inadequate remedial measures, when design flaws persisted and continued to cause serious harm to patients; (d) as a result, there was a heightened risk that customers would be instructed to take existing Novum LVPs out of service and that Baxter would completely pause all new sales of these pumps; and (e) based on the foregoing, Baxter's statements about the safety, efficacy, product rollout, customer feedback and sales prospects of the Novum LVPs were materially false and misleading.

The true extent of Defendants' fraud was revealed on July 31, 2025, when the Company announced that it had decided to "voluntarily and temporarily pause shipments and planned installations of the Novum LVP" and that the Company was "unable to currently commit to an exact timing for resuming shipment and installation for Novum LVPs." On this news, Baxter stock dropped 22.4 percent, closing at $21.76 on July 31, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Baxter's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Baxter International class action, go to www.faruqilaw.com/BAX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277106

December 07, 2025 8:17 AM EST | Source: Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Avantor To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in Avantor between March 5, 2024 and October 28, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Avantor, Inc. ("Avantor" or the "Company") (NYSE: AVTR) and reminds investors of the December 29, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Avantor's competitive positioning was weaker than Defendants had publicly represented; (2) Avantor was experiencing negative effects from increased competition; and (3) as a result, Defendants' representations about the Company's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis.

During the Class Period, Defendants misled investors by falsely touting the Company's competitive positioning and downplaying the effects of increased competition. For example, during an earnings call on July 26, 2024, in response to an analyst's question about whether Avantor was losing share to a competitor, Defendant Michael Stubblefield, then the Company's President and Chief Executive Officer, assured investors that Avantor's "lab business stacks up well against every number that certainly that we've seen," that "we continue to enhance our position," and that "we're really confident in our value proposition and our competitive position." Likewise, Defendants repeatedly pointed to Avantor's purported competitive advantages, such as its digital capabilities, as evidence that the Company would continue to enjoy strong competitive positioning.

Investors began to learn the truth about the effects of increased competition on Avantor's business on April 25, 2025, when the Company reported disappointing first quarter 2025 financial results, cut its guidance for 2025, and announced that Defendant Stubblefield would be stepping down from his roles as President and Chief Executive Officer. Defendants attributed Avantor's weak performance and outlook to "the impact of increased competitive intensity."

On this news, the price of Avantor common stock declined $2.57 per share, or more than 16.5%, from a close of $15.50 per share on April 24, 2025, to close at $12.93 per share on April 25, 2025

Then, on August 1, 2025, the Company reported disappointing second quarter 2025 financial results, including a year-over-year decrease in net sales, and further reduced the Company's 2025 guidance-now projecting organic revenue growth of -2% to 0%. Defendants again attributed Avantor's poor results and outlook to "increased competitive intensity," and further admitted that the Company did not expect the competitive environment to materially improve in the remainder of 2025 and weak performance would therefore likely persist.

In response to this news, the price of Avantor common stock declined $2.08 per share, or more than 15%, from a close of $13.44 per share on July 31, 2025, to close at $11.36 per share on August 1, 2025.

Then, on October 29, 2025, the Company reported weak third quarter 2025 financial results, including -5% organic revenue growth (below the guidance Defendants had provided in August), and a net loss of $712 million, which Defendants primarily attributed to a non-cash goodwill impairment charge of $785 million. Defendants revealed that the impairment charge was necessary due in part to "competitive pressures" that had "meaningfully impacted" the Company's margins, and further admitted that the Company had lost several large accounts

On this news, the price of Avantor common stock declined $3.50 per share, or more than 23%, from a close of $15.08 per share on October 28, 2025, to close at $11.58 per share on October 29, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Avantor's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Avantor class action, go to www.faruqilaw.com/AVTR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277105

December 07, 2025 8:20 AM EST | Source: Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In James Hardie To Contact Him Directly To Discuss Their Options

If you purchased or acquired securities in James Hardie between May 20, 2025 and August 18, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against James Hardie Industries plc ("James Hardie" or the "Company") (NYSE: JHX) and reminds investors of the December 23, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that James Hardie Industries plc misled investors about the strength of its key North America Fiber Cement segment between May 20 and August 18, 2025. Despite knowing by April and early May that distributors were destocking inventory, the company falsely claimed demand remained strong and that stock levels were "normal."

On August 19, 2025, James Hardie issued a press release announcing financial results for its first quarter ended June 30, 2025. Among other items, James Hardie reported a 29% decline in first-quarter profit and projected lower-than-expected fiscal 2026 earnings, citing high borrowing costs.

On this news, James Hardie's American Depositary Receipt ("ADR") price fell $9.79 per ADR, or 34.44%, to close at $18.64 per ADR on August 20, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding James Hardie's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the James Hardie class action, go to www.faruqilaw.com/JHX or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277118

December 07, 2025 8:21 AM EST | Source: Faruqi & Faruqi LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses in Bitdeer to Contact Him Directly to Discuss Their Options

If you purchased or acquired securities in Bitdeer between June 6, 2024 and November 10, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York--(Newsfile Corp. - December 7, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Bitdeer Technologies Group ("Bitdeer" or the "Company") (NASDAQ: BTDR) and reminds investors of the February 2, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that among other things, confidence in the Company's mass-production of its fourth-generation SEALMINER (A4) rigs using its SEAL04 ASIC (application-specific integrated circuit) chip technology was expected to have a chip energy efficiency of as low as 5J/TH. Defendants provided these positive statements to investors while, at the same time, disseminating false and materially misleading statements and/or concealing material adverse facts concerning the true state of Bitdeer's SEALMINER A4 project. Specifically, Defendants failed to disclose that the SEAL04 chip projected to have a chip-level energy efficiency of 5 J/TH would be ready for use in the A4 rigs with an expected mass production to begin in the second quarter 2025. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Bitdeer's securities at artificially inflated prices.

On November 10, 2025, Bitdeer issued a press release reporting its unaudited financial results for the third quarter of 2025. Among other items, Bitdeer reported earnings per share of -$1.28, significantly missing the consensus estimate of -$0.22. Bitdeer also disclosed that "development of [its] next-generation Seal 04 [ASIC chip] is significantly delayed."

On this news, Bitdeer's stock price fell $2.63 per share, or 14.9%, to close at $15.02 per share on November 11, 2025.

Then, on November 12, 2025, Bitdeer issues a press release "reporting a fire incident at its under-construction facility in Massillon, Ohio." According to the press release, "[t]he fire incident occurred on the afternoon of November 11" and "2 of the 26 buildings currently under construction sustained fire damage."

On this news, Bitdeer's stock price fell another $2.83 per share, or 20.3%, to close at $11.11 per share on November 13, 2025.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding Bitdeer's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

To learn more about the Bitdeer Technologies class action, go to www.faruqilaw.com/BTDR or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

Follow us for updates on LinkedIn, on X, or on Facebook.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277107